🔍

Samsrita Labs Ltd (539267)

📊 BSE: 539267 🏢 Healthcare Service Provider 📢 Latest filing: 03 Oct 2026

Latest quarterly results (Q4 FY26)

In its latest reported quarter, Q4 FY26, Samsrita Labs' revenue was ₹0.0 Cr, and net profit ₹-0.5 Cr; the operating margin was -750.0%.

Q4 FY26 (₹ Cr)	Value	YoY	QoQ
Revenue	₹0.0	—	—
Operating profit	₹-0.1	—	loss narrowed
Net profit	₹-0.5	—	loss narrowed
EPS (₹)	-0.21	—	loss narrowed
Operating margin	-750.0%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Samsrita Labs Calls EGM for ₹25 Cr Related-Party Sales, ₹1 Cr CCPS & ₹1 Cr Loan

🔵 WATCH ⭐ 9/10

OTHER 📅 03 Oct 2026, 03:16 PM

Samsrita Labs has issued a notice for an Extraordinary General Meeting (EGM) scheduled on October 26, 2026, seeking shareholder approval for key related-party transactions. The resolutions include sale of goods up to ₹25 crore to S Labs Hygiene Care Pvt Ltd, which is massive compared to Samsrita's FY26 turnover of just ₹1.81 lakhs. Additionally, the company seeks approval to invest up to ₹1 crore in CCPS of S Labs Hygiene Care and borrow up to ₹1 crore as an unsecured loan at 9% p.a. from Director Ravikanth Chopperla for working capital.

Proposed related-party sales limit of up to ₹25,00,00,000 to S Labs Hygiene Care Pvt Ltd from Oct 26, 2026 to Oct 25, 2027
Subscription to Compulsorily Convertible Preference Shares (CCPS) of S Labs Hygiene Care up to ₹1,00,00,000
Availing an unsecured loan up to ₹1,00,00,000 at 9.00% interest per annum from Non-Executive Director Ravikanth Chopperla
EGM scheduled for October 26, 2026, with the e-voting cut-off date set as October 19, 2026

💡 Track the outcome of the shareholder vote at the EGM on October 26, 2026, and monitor subsequent financial disclosures to see if the ₹25 crore related-party commercial activity translates into actual reported revenue.

Samsrita Labs Approves ₹26 Cr Related-Party Deals and ₹1 Cr Loan in Pet Care Pivot

🔵 WATCH ⭐ 9/10

BOARD_MEETING 📅 28 Sep 2026, 05:39 PM

Samsrita Labs' board has approved major related-party transactions with newly incorporated S Labs Hygiene Care Private Limited, an entity 80% owned by its Non-Executive Director Ravikanth Naga Pattabhi Chopperla. The company plans to invest up to ₹1.00 crore in Compulsory Convertible Preference Shares (CCPS) and enter into sale transactions of up to ₹25.00 crore in the pet care segment. Additionally, the company approved availing an unsecured working capital loan of up to ₹1.00 crore from the same director. These transactions, which are substantial relative to Samsrita's ₹28 crore market cap and negligible TTM revenue, require shareholder approval at the EGM on October 26, 2026.

Proposed investment of up to ₹1,00,00,000 in CCPS of S Labs Hygiene Care Private Limited
Approval of related-party sale transactions of up to ₹25,00,00,000 with S Labs Hygiene Care
Unsecured working capital loan of up to ₹1,00,00,000 from Non-Executive Director Ravikanth Chopperla
Target entity S Labs was incorporated on 10.07.2026, with the director holding an 80% equity stake
Extra-Ordinary General Meeting (EGM) scheduled for 26.10.2026 to seek shareholder approval

💡 Track the outcome of the shareholder vote at the EGM on October 26, 2026, and watch for subsequent execution disclosures regarding valuation metrics and revenue materialization from the ₹25 crore sales agreement.

Samsrita Labs reports zero deviation in ₹3.39 Cr preferential issue fund utilization

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Aug 2026, 04:21 PM

Samsrita Labs has submitted its quarterly statement confirming no deviation in the utilization of ₹3.39 crore raised via a preferential issue on July 18, 2025. The funds were earmarked for working capital (₹52.10 lakhs), new projects (₹132.46 lakhs), repayment of promoter loans (₹88.31 lakhs), and general corporate purposes (₹66.23 lakhs). As of June 30, 2026, the company reports that the actual utilization remains in line with the original objects. This transparency is notable given the company's current financial distress, including zero TTM revenue and negative net profit.

Total funds raised via preferential issue on 18-07-2025 amounted to ₹339.10 lakhs.
Allocation for investment into new projects or ventures stands at ₹132.46 lakhs.
Repayment of unsecured loans to Promoter Director was allocated ₹88.31 lakhs.
Reported deviation or variation for the quarter ended June 30, 2026, is Nil.
Company market cap is small at ₹26 Cr, making the ₹3.39 Cr fundraise significant at ~13% of market cap.

💡 Investors should monitor whether the ₹1.32 crore allocated for 'New Projects' translates into actual revenue, as the company currently reports zero TTM revenue and significant operating losses.

Samsrita Labs Reports Q1 FY27 Net Loss of ₹31.47 Lakhs on Zero Revenue

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 13 Aug 2026, 04:09 PM

Samsrita Labs continues to struggle with zero operational revenue for the quarter ended June 30, 2026. The standalone net loss widened to ₹31.47 lakhs, compared to a loss of ₹11.87 lakhs in the preceding quarter (March 2026). Total expenses nearly doubled sequentially to ₹31.47 lakhs, primarily driven by 'Other Expenses' of ₹21.55 lakhs. With a market cap of only ₹26 crore and a history of significant losses, the company's financial health remains extremely weak.

Revenue from operations remained at ₹0.00 for the quarter ended June 30, 2026.
Standalone net loss widened to ₹31.47 lakhs from ₹11.87 lakhs in the previous quarter.
Total expenses increased by approximately 87% quarter-on-quarter to ₹31.47 lakhs.
Employee benefit expenses rose to ₹9.80 lakhs from ₹7.83 lakhs in the preceding quarter.
The company's paid-up equity share capital stands at ₹2,274.97 lakhs.

💡 Investors should monitor whether the company can initiate any revenue-generating operations, as it has reported near-zero revenue for multiple quarters. The significant decline in promoter holding over the past year (from 48.25% to 25.44%) is a major red flag.

Samsrita Labs Reports Rs 18.87 Lakhs Consolidated Net Loss in Q1 FY27 on Zero Revenue

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 13 Aug 2026, 04:05 PM

Samsrita Labs continues to report zero operational revenue for the quarter ended June 30, 2026, maintaining its pre-revenue status. On a consolidated basis, the net loss narrowed to Rs 18.87 Lakhs compared to a loss of Rs 48.16 Lakhs in the year-ago period, aided by a Rs 12.60 Lakhs profit share from associate companies. Standalone expenses increased slightly to Rs 31.47 Lakhs from Rs 27.66 Lakhs YoY, primarily due to employee benefits and administrative costs. The company's financial health remains strained with a negative TTM PAT of approximately Rs 8 Cr and a market cap of only Rs 27 Cr.

Revenue from operations remained at Rs 0.00 for the quarter ended June 30, 2026.
Consolidated net loss narrowed to Rs 18.87 Lakhs from Rs 48.16 Lakhs in the corresponding quarter of the previous year.
Standalone total expenses rose to Rs 31.47 Lakhs, up from Rs 27.66 Lakhs YoY.
Associate companies (Krisani Bio Sciences and Qrops Advisory) contributed a profit share of Rs 12.60 Lakhs.
Paid-up equity share capital remains at Rs 2,274.97 Lakhs with a face value of Rs 10 per share.

💡 Investors should monitor the company's ability to generate any operational revenue in the healthcare sector, as it has remained largely non-operational for several quarters. The significant reduction in promoter holding over the past year (from 48.25% to 25.44%) is a critical red flag to watch.

Aug 13 Board Meeting to Approve Q1 FY27 Results; TTM Revenue Near Zero

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 05 Aug 2026, 02:29 PM

Samsrita Labs has scheduled a board meeting for August 13, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. The company is in a precarious financial state, reporting a net loss of ₹8.16 Cr in FY26 on negligible revenue of just ₹0.02 Cr. Investors should note the sharp decline in promoter holding, which fell from 48.25% in June 2025 to 25.44% by March 2026. The upcoming results are critical to see if the company has initiated any actual business operations.

Board meeting scheduled for August 13, 2026, to approve Q1 FY27 results.
Company reported a net loss of ₹8.16 Cr for the full year FY26.
Revenue for the most recent quarter (March 2026) was only ₹0.02 Cr.
Promoter holding has significantly decreased to 25.44% from 48.25% a year prior.
Market capitalization stands at a micro-cap level of ₹26 Cr.

💡 Monitor the August 13 results specifically for any signs of revenue generation, as the company has effectively operated without significant sales for the past year.

30th AGM Scheduled for Aug 10, 2026; Samsrita Labs Proposes MoA Object Clause Alteration

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Jul 2026, 02:52 PM

Samsrita Labs Limited has released its Annual Report for FY 2025-26 and scheduled its 30th Annual General Meeting (AGM) for August 10, 2026. The company is seeking shareholder approval for the appointment of two new directors, including an Independent Director for a five-year term. Notably, the agenda includes a special resolution to alter the Object Clause of the Memorandum of Association, indicating a potential shift or expansion in business activities. The cut-off date for determining voting eligibility is August 3, 2026.

30th Annual General Meeting to be held on August 10, 2026, via video conferencing.
Cut-off date for e-voting and AGM participation set for August 3, 2026.
Proposed appointment of Mr. Satyanarayana Murthy Varanasi as an Independent Director for a 5-year term until July 2031.
Special resolution proposed for the alteration of the Object Clause of the Memorandum of Association.
Consolidated financial statements include the performance of two associate companies for FY 2025-26.

💡 Investors should review the specific details of the proposed 'Alteration of Object Clause' in the full annual report to understand if the company is pivoting its core business strategy.

30th AGM Scheduled for Aug 10, 2026; Samsrita Labs Proposes MoA Object Clause Alteration

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 18 Jul 2026, 02:47 PM

Samsrita Labs Limited has scheduled its 30th Annual General Meeting (AGM) for August 10, 2026, to be conducted via video conferencing. The agenda includes the adoption of FY 2025-26 financial statements and the appointment of two new directors, including an Independent Director for a five-year term. Notably, the company is seeking shareholder approval to alter the Object Clause of its Memorandum of Association, which may indicate a strategic shift or expansion into new business areas. The cut-off date for voting eligibility is set for August 3, 2026.

30th Annual General Meeting scheduled for August 10, 2026, at 11:00 AM IST.
Cut-off date for e-voting and AGM participation is August 3, 2026.
Proposed appointment of Mr. Satyanarayana Murthy Varanasi as an Independent Director for a 5-year term until July 2031.
Special Resolution proposed for the alteration of the Object Clause of the Memorandum of Association.
Appointment of Mr. Ravi Kanth Naga Pattabhi Chopperla as a Non-Executive Director effective July 4, 2026.

💡 Investors should review the specific details of the 'Alteration of Object Clause' in the full Annual Report to understand if the company plans to diversify into new sectors.

View All 539267 Announcements on Live Market Tracking →